**Table 1.** Therapeutic optimizations and associated cost savings for 18 interventions.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | | **Previous therapy** | **Optimised**  **therapy** | | |  |  |
| **Optimization** | | **Factor product** | **Factor product** | **Cost savings** | | **Total cost savings** | **Cost savings/intervention** |
| **Product optimization** | | |  |  | | **$ 215,930.00** | **$ 23,992.22** |
| Nuwiq™ to Adynovate™ | |  |  |  | |  |  |
| Patient n°1 | | Nuwiq™ | Adynovate™ | $ -17,160.00 | |  |  |
|  | |  |  |  | | $ -17,160.00 | $ -17,160.00 |
| Xyntha™ to Adynovate™ | |  |  |  | |  |  |
| Patient n°2 | | Xyntha™ | Adynovate™ | $ 4,394.00 | |  |  |
| Patient n°3 | | Xyntha™ | Adynovate™ | $ -22,984.00 | |  |  |
| Patient n°4 | | Xyntha™ | Adynovate™ | $ 13,520.00 | |  |  |
| Total | |  |  |  | | $ -5,070.00 | $ -1,690.00 |
| Wilate™ to Adynovate™ | |  |  |  | |  |  |
| Patient n°5 | | Wilate™ | Adynovate™ | $ 80,730.00 | |  |  |
| Patient n°6 | | Wilate™ | Adynovate™ | $ 88,400.00 | |  |  |
| Patient n°7 | | Wilate™ | Adynovate™ | $ 134,290.00 | |  |  |
| Total | |  |  |  | | $ 303,420.00 | $ 101,140.00 |
| Alprolix™ to Rebinyn™ | |  |  |  | |  |  |
| Patient n°8 | | Alprolix™ | Rebinyn™ | $ -88,920.00 | |  |  |
|  | |  |  |  | | $ -88,920.00 | $ -88,920.00 |
| Kovaltry™ to Jivi™ | |  |  |  | |  |  |
| Patient n°9 | | Kovaltry™ | Jivi™ | $ 23,660.00 | |  |  |
|  | |  |  |  | | $ 23,660.00 | $ 23,660.00 |
| **Dose optimization keeping same drug** | | |  |  | | **$ 139,139.00** | **$ 15,459.89** |
| Adynovate™ | |  |  |  | |  |  |
| Patient n°10 | | Adynovate™ | Adynovate™ | $3,042.00 | |  |  |
| Patient n°11 | | Adynovate™ | Adynovate™ | $-13,520.00 | |  |  |
| Patient n°5 | | Adynovate™ | Adynovate™ | $-6,760.00 | |  |  |
| Patient n°3 | | Adynovate™ | Adynovate™ | $ 32,448.00 | |  |  |
| Total | |  |  |  | | $ 15,210.00 | $ 3,802.50 |
| Wilate™ | |  |  |  | |  |  |
| Patient n°12 | | Wilate™ | Wilate™ | $ 69,264.00 | |  |  |
| Patient n°13 | | Wilate™ | Wilate™ | $ -50,505.00 | |  |  |
| Patient n°14 | | Wilate™ | Wilate™ | $ 34,632.00 | |  |  |
| Patient n°12 | | Wilate™ | Wilate™ | $ 51,948.00 | |  |  |
| Total | |  |  |  | | $ 105,339.00 | $ 26,334.75 |
| Alprolix™ | |  |  |  | |  |  |
| Patient n°15 | | Alprolix™ | Alprolix™ | $ 18,590.00 | |  |  |
|  | |  |  |  | | $ 18,590.00 | $ 18,590.00 |
| **TOTAL** | **Total annual costs before intervention :**  **$1,734,681.00** | | **Total annual costs after intervention :**  **$1,379,612.00** | |  | **$ 355,069.00** | **$ 19,726.06** |

Note: Prices are expressed in $CAD. A negative cost savings corresponds to an additional cost.